GlaxoSmithKline today announced the start of an international Phase III trial of its investigational cancer treatment Tykerb? (lapatinib) in squamous cell carcinoma of the head and neck (SCCHN).
Data show significant asthma control and improved lung function with Symbicort.
Dynavax Technologies Corporation (NASDAQ: DVAX) reported interim data from the first year of its two-year ragweed allergy trial known as DARTT, including a prespecified regional analysis of sites that clearly showed a therapeutic benefit of TOLAMBA in the Midwest.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
New England Journal of Medicine today publishes results of largest ever study completed investigating the effect of treatment on mortality and morbidity in patients with chronic obstructive pulmonary disease (COPD).
New research suggests that reducing the number of falls suffered by seniors in nursing homes may be helped by taking a vitamin, along with other measures known to decrease falls.
Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk of the disease, according to two randomized, blinded clinical trials in the February 21 Journal of the National Cancer Institute. The trials found that the breast cancer risk reduction persists long after women stop taking tamoxifen.
Lexington International LLC is proud to announce the landmark achievement of US Food & Drug Administration (FDA) clearance for their medical laser device, the HairMax LaserComb?.
Health Canada, the Canadian government regulatory agency, has approved wide-ranging new health claims for COLD-fX, the most popular cold/flu remedy in Canada.
Merck & Co., Inc. updated the prescribing information for ROTATEQ? (rotavirus vaccine, live, oral pentavalent), the Company’s vaccine to help prevent rotavirus gastroenteritis in infants and children.